Pharmacy

The rare disease community struggles to balance care with costs.

While aggressive early intervention may be useful for diabetes patients, that intervention must be sustained.

These are the important policies to watch out for in 2019.

CMS introduced indication-based formularies as a voluntary tool for plans to implement in 2020.

Are accelerated approvals having as much impact as the FDA hopes?

A new study has revealing findings about the effects of front-end opioid prescribing for knee, hip, and shoulder joint replacement patients.

How to manage drug cost in a value-based world.

The chain’s move is an attempt to increase relationships with traditionally-loyal pharmacy patients.

Managed Healthcare Executive’s Managed Care Pharmacy Survey identifies different ways specialty pharmacy stakeholders believe they can reduce industry costs moving forward.

As CBD, or cannabidiol, surges in popularity, the FDA held its first public hearing on the chemical that claims to help with a variety of ailments including pain and anxiety.

A new survey shows that while many healthcare executives recognize drug diversion as a problem, few admit to it happening in their organization.

New study compares every state using data like opioid prescriptions and overdose rates to determine where drug problems hit hardest.

The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.

From drug price concerns to the evolving role of PBMs to the influence of specialty pharmaceuticals, what healthcare executives think about the future of pharmacy.

How will payers, providers, and patients respond when a $2 million drug drops into the market?

In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.

With a more than $2 million price tag, how are payers going to deal with the recently approved Zolgensma?

Why hospital pharmacists are playing an increasingly-large role in patient care and why their involvement can boost medication outcomes and reduce errors.

Is real-world evidence up to the task of gaining new indications?

As pharmacies get deeper into chronic care treatment, what will it mean for both pharmacy and the world of managed care?

Here are five key metrics that executives should pay attention to as they navigate challenges.

The United States pays much higher drug prices than other countries. Could reference pricing be the fix?

Managed Healthcare Executive has identified 10 emerging industry leaders, working in the areas of pharmacy, health plans, health systems, and technology.

Drug costs are a hot political topic, but just how much do they disrupt healthcare?

Asembia offers broad coverage across specialty pharmacy.

Key ways healthcare executives can improve therapy compliance.

Pharmacists are in a unique position to improve orphan drug and precision medicine channels.

Experts offer their thoughts on what the specialty pharmacy industry will look like over the next year.

As the healthcare landscape continues to change at a rapid pace, drug manufacturers need to take a long, hard look at their marketing and commercialization options.

With so many new immunotherapy treatments on the horizon, pharmacists need to understand the ins and outs of immuno-oncology biomarkers to best serve their patients.